AMRX — Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $796 million, up 10% year-over-year.
• Adjusted EBITDA: $206 million, up 12%.
• Adjusted EPS: $0.30, up 20%.
• Affordable Medicines Revenue: $490 million, up 13%.
• Specialty Revenue: $149 million, up 17%.
• AvKARE Revenue: $157 million, down 4%.
• Adjusted Gross Margin: 46.2%, up 60 basis points year-over-year.
• Interest Expense Reduction: Successfully repriced $2.084 billion Term Loan B, saving $12 million annually.

2. Strategic Updates and Business Highlights

• Amneal is undergoing a transformative phase, focusing on expanding its portfolio in Affordable Medicines, biosimilars, and Specialty drugs.
• The company is increasing capacity in Women's Health products, particularly transdermal patches, in response to rising demand.
• The pending acquisition of Kashiv will enhance Amneal's capabilities in biosimilars, positioning it as a fully integrated player in this market.
• Strong performance from Specialty products, particularly CREXONT and BREKIYA, with ongoing R&D efforts to expand the pipeline.
• Amneal's Brookhaven site was selected for the FDA's PreCheck Pilot Program, enhancing its manufacturing credibility.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased by $50 million to a range of $3.1 billion to $3.2 billion.
• Adjusted EBITDA Guidance: Raised by $10 million to a range of $750 million to $780 million.
• Adjusted EPS Guidance: Increased by $0.01 to a range of $0.96 to $1.06.
• CapEx Expectations: Increased from $110 million to approximately $150 million to support growth initiatives.
• Anticipated negative impact of approximately $20 million due to flooding at the India facility.

4. Bad News, Challenges, or Points of Concern

• AvKARE Revenue Decline: Down 4% due to a low-margin distribution business, indicating potential challenges in this segment.
• Flooding Impact: Recent flooding in India may limit production for select products, although operations are expected to resume soon.
• Market Competition: The company faces competitive pressures in both the biosimilars and Affordable Medicines sectors, particularly as more products lose exclusivity.

5. Notable Q&A Insights

• Lanreotide Approval: Expected in Q3 2026; the company remains optimistic about no significant FDA gating items.
• Biosimilar Pipeline: Six commercial biosimilars expected by 2027, with a total addressable market (TAM) of $14 billion.
• CREXONT Uptake: 80% of prescriptions are now from general neurologists, indicating strong market acceptance.
• Market Potential for Estrogen Patches: Significant growth anticipated, with potential revenue increases of $1 billion to $2 billion from existing and new product launches by 2030.
• Focus on Specialty M&A: Amneal is exploring acquisitions to leverage its existing commercial infrastructure, particularly in neurology and oncology.

Overall, Amneal Pharmaceuticals reported strong financial performance in Q2 2026, with positive growth across multiple segments and a strategic focus on expanding its biosimilars and Specialty portfolios. However, challenges such as revenue declines in certain areas and operational risks from external factors remain points of concern.